BioSpace News Archive

Voyager Therapeutics Announces New Data Presentati

Allergan, Richter Depression Drug Succeeds in Phase III

In this study, the primary efficacy objective was met for both Cariprazine 1.5mg and 3mg dose groups.

December 18, 2017

·

12 min read

Biotech Beach

Creative Medical Technology Release: “Urologist to the Stars” Dr. Alexander Gershman Begins Treating Patients With Patented Caverstem Stem Cell Procedure for Drug Refractory Erectile Dysfunction

Creative Medical Technology announced today initiation of patient treatments using its patented Caverstem procedure by Dr. Alexander Gershman.

December 18, 2017

·

3 min read

Business

Aytu BioScience Announces Appointment of David Green as CFO

Mr. Green is a highly accomplished CFO, who brings an extensive array of financial, accounting, and operational experience to Aytu.

December 18, 2017

·

5 min read

Business

InVivo Therapeutics Announces Executive Management and Board Changes

InVivo Therapeutics Corporation today announced that Richard Toselli, M.D., has been appointed Acting Chief Executive Officer of InVivo, replacing Mark D. Perrin, who has resigned as Chief Executive Officer and Chairman of InVivo’s Board of Directors.

December 18, 2017

·

6 min read

Pharm Country

Saama’s Life Science Analytics Cloud Named One of the Most Innovative Products of 2017 by PM360

Saama’s Life Science Analytics Cloud was selected over hundreds of other entries to be part of PM360’s 6th Annual Innovations Issue, published each December.

December 18, 2017

·

4 min read

Policy

IntelGenx Site Obtains GMP Compliant Rating From Health Canada for Manufacturing and Packaging Activities

The Company successfully achieved a GMP compliant rating, allowing the site to conduct licensable commercial manufacturing and packaging activities of finished dosage forms.

December 18, 2017

·

3 min read

Drug Development

FDA Accepts Biologics License Application for Fremanezumab with Priority Review for Prevention of Migraine and Grants Fast Track Designation for Cluster Headache Development Program

Trial participant recruitment is now underway and the studies are expected to conclude in early 2019.

December 18, 2017

·

10 min read

Biotech Beach

The Cryoport Biotech Activity Index Decreases 7.1% In Third Quarter of 2017; While the Total Number of Clinical Trials Increases to 934 Worldwide

The decrease in the CoBRA Index was primarily due to the termination of a Phase III trial and pauses in dosing for several early stage trials.